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Heterozygous Loss-of-Function Mutations
in YAP1 Cause Both Isolated and Syndromic
Optic Fissure Closure Defects
Kathleen A. Williamson,1,8 Joe Rainger,1,8 James A.B. Floyd,2 Morad Ansari,1 Alison Meynert,1
Kishan V. Aldridge,1 Jacqueline K. Rainger,1 Carl A. Anderson,2 Anthony T. Moore,3,7
Matthew E. Hurles,2 Angus Clarke,4 Veronica van Heyningen,1 Alain Verloes,5 Martin S. Taylor,1
Andrew O.M. Wilkie,6 UK10K Consortium, and David R. FitzPatrick1,*
Exome sequence analysis of affected individuals from two families with autosomal-dominant inheritance of coloboma identified two
different cosegregating heterozygous nonsense mutations (c.370C>T [p.Arg124*] and c. 1066G>T [p.Glu356*]) in YAP1. The pheno-
types of the affected families differed in that one included no extraocular features and the other manifested with highly variable
multisystem involvement, including hearing loss, intellectual disability, hematuria, and orofacial clefting. A combined LOD score of
4.2 was obtained for the association between YAP1 loss-of-function mutations and the phenotype in these families. YAP1 encodes an
effector of the HIPPO-pathway-induced growth response, and whole-mount in situ hybridization in mouse embryos has shown that
Yap1 is strongly expressed in the eye, brain, and fusing facial processes. RT-PCR showed that an alternative transcription start site
(TSS) in intron 1 of YAP1 and Yap1 is widely used in human and mouse development, respectively. Transcripts from the alternative
TSS are predicted to initiate at codon Met179 relative to the canonical transcript (RefSeq NM_001130145). In these alternative
transcripts, the c.370C>T mutation in family 1305 is within the 50 UTR and cannot result in nonsense-mediated decay (NMD). The
c. 1066G>T mutation in family 132 should result in NMD in transcripts from either TSS. Amelioration of the phenotype by the alter-
native transcripts provides a plausible explanation for the phenotypic differences between the families.Occurring in ~1 in 5,000 live births,1 ocular coloboma is
themost commonmajor eyemalformation and is typically
due to an optic fissure closure defect (OFCD) during devel-
opment.2 The clinical impact of an OFCD is strongly corre-
lated with the extent and location of the closure defect in
an individual.3 Small optic nerve and choroidoretinal
OFCDs (not involving the macula) can be asymptomatic
and can be discovered on investigation of apparently unaf-
fected parents of severely affected children.1 OFCDs
involving only the iris typically present as inferonasal
‘‘keyhole’’ defects, which can be of cosmetic significance
and cause intolerance of bright light. However, bilateral
OFCDs might be a significant cause of visual impairment
during childhood as a result of associated severe micro-
phthalmia, failure of macula development, and/or retinal
detachment.4
Segregation analysis in families has indicated that there
is a strong genetic component to both bilateral and unilat-
eral OFCDs.1 In most individuals with an OFCD, the
genetic basis of the malformation is not known. Mutations
in OFCD cases have been identified in genes more
commonly associated with bilateral anophthalmia (SOX2
[MIM 184429],5,6 OTX2 [MIM 600037],7 STRA6 [MIM
610745]8), holoprosencephaly (MIM 142945) (SHH
[MIM 600725]9), or aniridia (MIM 102210) (PAX6 [MIM1Medical Research Council Human Genetics Unit, Medical Research Counci
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The Americ607108]10,11). OFCDs can also be a component of many
different multisystem developmental syndromes, such as
CHARGE syndrome (MIM 214800, caused by mutations
in CHD7 [MIM 608892]; see GeneReviews in Web Re-
sources) and Baraitser-Winter syndrome (MIM 243310,
caused by mutations in ACTB1 [MIM 102630] and
ACTG1 [MIM 102560]12,13). Recently, ABCB6 (MIM
605452) was identified as a strong candidate gene via posi-
tional cloning in a large Chinese family affected by auto-
somal-dominant OFCDs.14
As part of the rare-disease component of the UK10K
project, whole-exome sequencing was performed on an
affected uncle-niece pair with bilateral OFCDs (Figure 1,
family 1305 individuals II:2 and III:1; clinical examina-
tion by A.V.). This study was approved by the UK Multire-
gional Ethics Committee (reference 06/MRE00/76), and
informed consent was obtained from the participating
families. Exome sequencing was performed as previously
described.15 Sequences were aligned with the Burrows-
Wheeler Aligner v.0.5.9, duplicates were marked with
Picard v.1.43, indels were realigned and base quality scores
were recalibrated with the Genome Analysis Toolkit
(GATK) v.1.0.5506, and variants were called only with
the GATK Unified Genotyper. The shared variant filtering
in this family is summarized in Table 1. No significantl Institute of Genetics and Molecular Medicine, University of Edinburgh,
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Figure 1. Position and Consequences of YAP1 Mutations
(A) Pedigree structure of family 1305 (F1305). The symbol key is shown on the left. DNAwas available from three affected (II:2, II:3, and
III:1) and two unaffected (I:1 and I:2) individuals.
(B) An abridged version of the published pedigree of family 132 (F132, Ravine et al.17) shows affected individuals from whom DNA
samples were available.
(C and D) Representative chromatograms of the confirmatory Sanger sequencing that was performed in all individuals fromwhomDNA
was available in families 1305 and 132.
(E) A diagram of the domain structure of YAP1. The amino acid numbers indicating the beginning and end of each domain are shown
above relative to isoform 1 (P46937, UniProt). The positions of the exon junctions are indicated by the vertical gray dashed lines. The
positions of the nonsensemutations are shown in red text, and the probably nonpathogenicmissensemutations are shown in gray text.
The probable initiating methionine used in transcripts from the alternative transcription start site (TSS) is indicated by Met179.
(F and H) Diagrams of the 50 end of the gene models for the canonical and alternative TSSs in human and mouse, respectively. In both
species, the most 50 TSS is canonical and encodes transcripts with an open reading frame that uses the initiation methionine Met1. The
TSS in intron 1 of the canonical transcript splices to the same exon 2, but in this transcript, the initiating methionine is equivalent to
Met179 of the canonical transcript.
(G and I) A gel photograph shows the results of RT-PCR using primers indicated by the red arrows on the cognate gene models and the
tissues indicated above each lane. This shows that the alternative TSS was present in all examined tissues.
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Table 1. Shared Variant Filtering for Family 1305
Family 1305
Uncle (II:2) Niece (III:1)
VCF code COL5103588 COL5103589
Average depth 36.6 36.5
Total number of variant calls 101,283 104,337
Number of variants passing
quality filters
42,822 43,786
Number of variants not in dbSNP 1,522 1,631
Number of nonsense or essential
splice (SNV) variants
16 9
Shared variants YAP1 c.370C>T (p.Arg124*)
ETFDH c.1093G>T (p.Glu365*)
Abbreviations are as follows: SNV, single-nucleotide variant; and VCF, variant
call format.variants were detected in any of the known genes associ-
ated with eye malformations (all exome sequenced sam-
ples had been prescreened for the elimination of those
with SOX2, OTX2, or PAX6 paired box mutations). Only
two shared mutations were detected after filtering on the
hypothesis that a rare, clear loss-of-function (LOF) muta-
tion represented the causative variant.Oneof thesewashet-
erozygous nonsense mutation c.1093G>T (p.Glu365*) in
ETFDH (MIM 231675). Monoallelic LOF mutations in
ETFDH arenot associatedwithdiseasephenotypes,whereas
the biallelic state causes glutaric acidemia type II (MIM
231680). Given that no other plausible pathogenic ETFDH
alleles were identified in either individual, we assumed that
each is a carrier of this rare autosomal-recessive disease. The
other LOF mutation identified was heterozygous nonsense
mutation c.370C>T (p.Arg124*) in exon 2 of yes-associated
protein 1 (YAP1 [MIM 606608], RefSeq accession number
NM_001130145.2 [canonical transcript variant 1], RefSeq
NG_029530.1 [genomic]) (Figure 1). Thismutationwas pre-
sent in all four affected individuals in the family and had
been inherited from the unaffected grandfather (Figure 1,
family 1305 individual I:1). Therewas no evidence ofmosa-
icism for this apparently nonpenetrant mutation in the
peripheral-blood-derived DNA from the grandfather, and
no other tissues were available for study. His parents were
not available for testing to determine whether he had
inherited the mutation. Oligonucleotides used for PCR
amplification of YAP1 are shown in Table S1, available
online. No other LOF mutations in YAP1 were identified
in the 700 noncoloboma exomes in the UK10K Rare
Diseases Group or in the NHLBI Exome Sequencing Project
Exome Variant Server (EVS). The UK10K coloboma exome
data (99 exomes, including 75 OFCD-affected individuals
from 58 different families) did not contain any missense
mutations that were not also present in EVS.
A separate exome sequencing study on ten unrelated in-
dividuals with severe bilateral eye malformations identi-The Americfied an individual with a different nonsense mutation in
exon 7 of YAP1: c.1066G>T (p.Glu356*) (Figure 1, family
132 [abridged affected-only pedigree]). This person has
bilateral OFCDs and is part of a large family affected by a
previously reported multisystem autosomal-dominant
disorder featuring OFCDs, cleft lip with or without cleft
palate, intellectual disability, hematuria (without renal
impairment or dysplasia), and sensorineural hearing loss
(MIM 120433, clinical examination by A.O.M.W.)16,17
(Table 2). All 13 of the affected family members who
were available for testing were found to carry the same
nonsense mutation (Figure 1, family132), giving a
maximum LOD score of 3.31 at a recombination rate of 0
under the assumption of a maximum allele frequency of
0.0002 (LOD ¼ 3.309 using maximum allele frequency ¼
0.001). The combined LOD score for the segregation of
nonsense mutations in families 1305 and 132 was 4.2.
Another family has been reported with a phenotype
similar to that of family 132 (family 4, affected by OFCDs
and cleft lip and palate).1 A causative mutation in YAP1
could not be identified in this family.
On reviewing the array-based comparative genomic
hybridization data from 210 individuals with eye malfor-
mations, we identified an adult female who has bilateral
OFCDs associated with intellectual disability and a
large interstitial deletion of 11q (chr11: 84,886,352–
113,918,790, clinical examination by A.T.M.). This dele-
tion, which occurred de novo, includes YAP1 (Figure S1,
DECIPHER accession number 282360) in addition to 434
other genes. No other copy-number variants were detected
for this region of 11q in the remaining individuals. The
association between this deletion and bilateral OFCDs is
compatible with the notion that YAP1 haploinsufficiency
is the causative genetic effect. However, no strong conclu-
sion could be drawn in this regard given the large number
of other genes in the deleted interval.
Resequencing of YAP1 in a panel of 336 unrelated OFCD-
affected individuals (with no overlap with those sent for
exome sequencing) revealed only three rare missense
mutations (Figure 1). PCR-based mutation screening ana-
lyses were performed as previously described.7 In family
177, a c.416C>T (p.Pro139Leu) mutation affects a
conserved residue that is not associated with a known
domain of YAP1 and that is substituted by alanine in
data for a YAP1 allele present in the EVS (Figure S3). The
mutation does not segregate with the OFCD phenotype
in family 177 (Figure S2). The probands in family 275
(affected by c.988A>G [p.Met330Val]) and family 4162
(affected by c.1385G>A [p.Gly462Glu]) have bilateral
OFCDs with microphthalmia and bilateral anophthalmia,
respectively. In both cases, there is no family history of eye
malformations and no parental samples were available. A
single rare missense mutation—c.680C>T (p.Ser227Leu)
in family 443—was identified in the UK10K coloboma
exome data. This single-nucleotide variant (SNV) was
present in 1/13,003 alleles in the EVS (rs376161041).
Family 443 is a multiplex consanguineous family, whichan Journal of Human Genetics 94, 295–302, February 6, 2014 297
Table 2. Clinical Features in Family 132
Family 132
I-2 II-1 II-2 II-3 II-4 III-1 III-2 III-3 III-4 III-5 III-6 III-7 IV-1
Sex F F M F F M F F F F M F F
Age (years) at last assessment 67 50 49 46 44 28 27 25 24 19 14 12 5
Iris coloboma Y Y Y Y ? N bilateral ectopic
pupils
Y Y Y Y ? Y
Chorioretinal coloboma Y Y ? Y N ? Y Y Y Y N ? Y
Microphthalmia Y N Y ? Y N Y N ? Y Y Y Y
Impaired extraocular muscle function Y N ? ? ? Y Y N ? N Y ? Y
Cataract Y Y ? Y N N Y N ? N N ? N
Cleft palate or cleft uvula N N Y N Y N N Y N N Y Y N
Cleft lip N N Y N Y N N N N N Y Y N
Hearing impairment Y Y Y Y Y ? Y N Y Y Y Y ?
Learning difficulties ? ? Y ? Y Y ? ? Y ? Y Y ?
Hematuria N Y ? ? Y N Y ? ? Y ? N ?
Abbreviations are as follows: F, female; N, no; M, male; Y, yes; and ?, unknown.is compatible with autosomal-recessive inheritance of the
eye malformation. No other YAP1 variant could be identi-
fied in the proband, and this SNV did not seem a likely
cause of the phenotype in this family. Neither this SNV
nor those in families 275 or 4162 change an evolutionarily
conserved residue (Figure S3). A custom R script (available
upon request) was used for examining the distribution of
the rare missense mutations with respect to their position
in the open reading frame. The missense mutations identi-
fied in the coloboma exome and resequencing data
appeared to have a very similar distribution to that of the
presumably nonpathogenic missense mutations reported
in the EVS (Figure S4). In summary, none of the nonsynon-
ymous variants in the coloboma cohorts can be considered
plausible disease-causing variants.
YAP1 encodes transcriptional coactivator YAP1, which,
among others, was used in defining the WW domain,18
found in approximately 100 human gene products. This
domain mediates protein-protein interaction via the 4
amino acid proline-rich (PPxY) motif,18 phosphorylated
serine-proline (pSP) motifs,19 or WW domains of other
proteins. There are at least eight splice isoforms of YAP1,
and each has the potential to encode an altered primary
amino acid sequence.20,21 These can be divided into two
groups on the basis of whether the N-terminal half of the
protein has one or two WW domains via inclusion or
exclusion of coding exon 4. In both groups, there is alter-
native splicing of coding exon 6 and alternate use of a
splice donor site for coding exon 5 (Figure 1).
The canonical role of YAP1 appears to be the major
effector of the HIPPO signaling pathway, which is impor-
tant in the control of organ size during development and
is of increasing interest in cancer biology. The subcellular
localization of YAP1 and its close homolog, WW-domain-298 The American Journal of Human Genetics 94, 295–302, Februarycontaining transcription regulator 1 (WWTR1, also known
as TAZ), is controlled by serine-threonine kinases LATS1
and LATS2 and their modulator, MOB1A, which in turn
are regulated by the kinases STK3 and STK4 and their
modulator, SAV1. Phosphorylated YAP1 is either retained
in the cytoplasm or degraded, whereas nonphosphory-
lated YAP1 is translocated to the nucleus and functions
as a transcriptional coactivator with several different
transcription factors, the best studied of which are
TEAD1–TEAD4, whichmediate the cell-proliferative effects
of YAP1.
Complete inactivation of Yap1 in mice results in devel-
opmental arrest at 8.5 days postcoitus (dpc,)22 leading to
multiple system defects, including yolk sac vasculogenesis
and embryonic axis elongation. In addition to being
involved in HIPPO signaling, YAP1 has also been impli-
cated in the modulation of BMP signaling via interaction
with Smad7,19 WNT signaling via interaction with b-cate-
nin,23 and NOTCH signaling via upregulation of JAG1
(MIM 601920).24 YAP1 itself is upregulated by hedgehog
signaling.25
A direct role for YAP1 in eye development has not previ-
ously been identified. To examine site- and stage-specific
expression in mouse embryos, we used both whole-mount
in situ hybridizationwith riboprobes targeted to the 30 UTR
of Yap1 and immunohistochemistry (IHC). This showed
expression in the otic vesicle and future brainstem at
9.5 dpc. Expression in the eye was first visible at 10.5 dpc
and continued as strong expression on the distal optic
cup and overlying surface ectoderm. IHC with the primary
antibodies anti-YAP1 (ab56701, Abcam) and anti-PAX2
(PRB-276P, Covance) confirmed this but also suggested
that the protein is present in the developing lens and the
optic stalk (Figure 2). Using PAX2 as a marker for the optic6, 2014
Figure 2. Developmental Expression of YAP1 and Yap1 during Mouse Development
The top panel shows optical-projection-tomography images of Yap1 expression detected by whole-mount in situ hybridization on
mouse embryos as 9.5, 10.5, 11.5, and 12.5 dpc. At each stage, a 3D reconstruction of the whole embryo is presented on the left. The
dashed and numbered white lines indicate the position and angle of the digital sections that are shown to the right of the 3D
(legend continued on next page)
The American Journal of Human Genetics 94, 295–302, February 6, 2014 299
fissure edges, we observed that cells in the periocular
mesenchyme (in the gap between the edges) were strongly
YAP1 positive. The origin and fate of these interedge cells
are not known. Expression was also apparent in the devel-
oping brain and in both the maxillary and frontonasal
components of the primary palate.
To examine expression in humans, we attempted to
quantify YAP1 in two control lymphoblastoid cell lines
(LCLs) and an LCL from the proband in family 132. No
cell line was available from any affected member of family
1305. However, YAP1 expression could not be detected.
One might suspect that these mutations should result in
nonsense-mediated decay (NMD) affecting all the reported
splice isoforms and thus lead to haploinsufficiency in all
tissues. However, this does not explain the clear pheno-
typic differences between the families. The apparently
isolated bilateral OFCD phenotype with one unaffected
individual showing complete nonpenetrance in family
1305 contrasted with the broader spectrum of develop-
mental phenotypes in family 132.
A potential explanation for the phenotypic differences
between the two families could be YAP1 expression from
an alternative transcriptional start site (TSS). To investigate
this possibility, we identified TSSs through genomic map-
ping of publicly available transcript data from both mouse
and human by using spliced expressed sequence tags
(ESTs) and cap analysis of gene expression (CAGE) tags.26
CAGE libraries were constructed with a technique that
captures the 50 ends of 50 capped mRNAs. The main pro-
moter for YAP1 strongly and broadly expressed a mean of
33 CAGE tags per million (tpm) and a maximum of
140 tpm. An additional TSS exists in intron 1, and a
maximum expression of 1.7 tpm was found in HepG2
cells. This alternative TSS is represented by RefSeq tran-
script NM_001195045 and supported by at least seven
spliced ESTs and a ‘‘full-length’’ mRNA (AK316116). The
intron 1 TSS was maximally expressed in carcinoma cell
lines but was detected in adult eye-derived tissue samples
at >1 per million CAGE tags. The alternative intron 1
TSS was also supported in mouse via multiple spliced
ESTs (e.g., CJ167646) and CAGE tags. Mouse expression
of this TSS was detected at low levels in multiple tissues
and cell types, including adult liver and lung.
We designed RT-PCR assays specific to each TSS (Table
S1) and performed reverse transcription by using
SuperScript III (Life Technologies). The mouse differs
from the human in that it has two different 30 splice sites
in the first exon in the transcripts from the alternative
TSS. Amplification from a cDNA template derived fromrepresentation for each stage. The boxed white sections indicate regi
for the highlighted tissues are as follows: OV, optic vesicle; OtV, otic v
VT, ventral telencephalon. Yap1 expression is indicated in green. Th
from the mouse embryonic eye at 10.5 dpc with antibodies specific
with DAPI. A diagram below indicates the position of the sections
through the optic stalk (OS); sections B and C both show the neural re
from sections B and C indicate nuclear staining for YAP1 in the RPE
gins, respectively.
300 The American Journal of Human Genetics 94, 295–302, Februaryhuman fetal brain and from mouse embryonic brain, eye,
kidney, whole embryo, and various adult tissues showed
that both TSSs were used in every developmental and adult
tissue examined (Figures 1G and 1I).
To determine whether expression from the alternative
TSS could underlie the differences in the phenotypes
from the two families, we evaluated where the mutations
identified in families 1305 and 132 were located in these
transcripts. The position of the nonsense mutation in fam-
ily 132 was in the coding sequence of all transcripts com-
ing from either TSS. However, the alternative transcript
contained the site of the family 1305 nonsense mutation
in the 50 UTR rather than in the coding sequence (Figures
1E and 1F), and it was thus invisible to NMD. Thus, in
family 1305, partial rescue of YAP1 haploinsufficiency by
the transcripts from the alternative TSS provides a plau-
sible explanation for the more restricted phenotype.
Unfortunately, we were not able to test the differential
effect on NMD directly because we did not have access to
expressing cell lines or tissues.
However, if such an effect exists, it would suggest that
the developing eye is the only tissue that has a dosage-
critical requirement for transcripts derived from the canon-
ical TSS. It is not clear why the optic fissure should be
particularly sensitive to alteration in YAP1 dosage. The
best-studied function of YAP1 is induction of cellular pro-
liferation. Exquisite genetic control of cell growth within
the optic vesicle (OV) enables the edges of the optic fissure
to appose and subsequently fuse. Reducing YAP1 activity
in or around the OV might alter this program of growth
to limit or prevent apposition and thus lead to coloboma.
Other plausible hypotheses, mentioned above, relate the
developmental pathology to noncanonical roles of YAP1
in the SHH and BMP signaling pathways. Further analysis
of the site- and stage-specific consequences of Yap1 loss of
function in model organisms is required before any con-
clusions can be drawn.
Transcripts derived from the alternative TSS have consid-
erable biological interest given that they cannot encode
YAP1 with an intact WW1 domain, but they are predicted
to encode either a WW2 domain alone or no WW domain
at all depending on subsequent alternative splicing. It
has recently been shown that both WW1 and WW2
domains are required for YAP1 to bind the Bmp signaling
effector Smad1.19 However, YAP1 with the WW1 domain
alone mediates binding of the Bmp signaling inhibitor
Smad7.19 Intriguingly, depletion of Smad7 in mouse em-
bryos results in eye malformation, including coloboma.27
Given the previous identification of mutations in genesons that are presented at higher magnification. The abbreviations
esicle; PA, pharyngeal arch; e, eye; PrP, fusing primary palate; and
e bottom panel shows immunohistochemical staining of sections
to YAP1 (green) and PAX2 (red). Nuclear staining was performed
along the proximodistal axis of the developing eye. Section A is
tina (NR) and lens (L). Higher-magnification images of boxed areas
and in the periocular mesenchyme between the optic fissure mar-
6, 2014
encoding BMP signaling molecules and antagonists in
human eye malformations,28–32 it will be important to
investigate the effects of YAP1 isoforms with only the
WW2 domain on this system.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://www.cell.com/AJHG.Consortia
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